CRDF - NASDAQ

Cardiff Oncology, Inc.

Cardiff Oncology, Inc.

CRDFยทNASDAQ

$1.51

+7.5%
HealthcareBiotechnology

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$103.24M
EPS-0.6900
P/E Ratio-2.19
Earnings Date07/30/2026
Cardiff Oncology, Inc.

Cardiff Oncology, Inc. Fair Value Envelope

CRDF ยท NASDAQ

Our analysis suggests that CRDF has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.51, this represents a potential HIDDEN relative to our calculated worth for Cardiff Oncology, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.51

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$248.2M
+ Cash & Equivalents$17.5M
Firm Value-$230.8M
- Debt$832.0K
Equity Value-$231.6M
/ Shares Outstanding66,525,854B
DCF Value-$3
OVERVALUED BY 331%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$37.7M
-$37.5M
-$37.3M
-$37.1M
-$37.0M
-$36.8M
-$36.6M
-$36.4M
-$36.2M
-$36.0M
Maintenance CapEx
-$8.8K
-$8.7K
-$8.7K
-$8.6K
-$8.6K
-$8.5K
-$8.5K
-$8.4K
-$8.4K
-$8.4K
Owner Earnings
-$37.7M
-$37.5M
-$37.4M
-$37.2M
-$37.0M
-$36.8M
-$36.6M
-$36.4M
-$36.2M
-$36.0M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$34.9M
-$32.2M
-$29.6M
-$27.3M
-$25.2M
-$23.2M
-$21.3M
-$19.7M
-$18.1M
-$16.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your CRDF research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.